Small Molecules

PX-478

Development Status A multicenter Phase 1 dose escalation trial of PX-478 in patients with advanced metastatic cancer has been initiated. This trial is designed to determine the safety, tolerability, pharmacokinetics and the effect of PX-478 on HIF-1α. For information on PX-478 clinical trials, please visit PX-478 Phase 1 trial description posted on ClinicalTrials.gov.